Intestinal microbiota and pancreatic diseases
PDF (Русский)
DOCX (Українська)


acute pancreatitis, chronic pancreatitis, pancreatic cancer, intestinal dysbiosis, intestinal permeability, treatment

How to Cite

Gubergrits, N. B., Byelyayeva, N. V., Klochkov, A. Y., Lukashevich, G. M., Rakhmetova, V. S., P. G. Fomenko, P. G. F., & Yaroshenko, L. A. (2019). Intestinal microbiota and pancreatic diseases. Herald of Pancreatic Club, 45(4), 17-29.

Abstract views: 18
PDF Downloads: 12 PDF Downloads: 3 PDF Downloads: 2


The article presents a detailed literature review on the role of intestinal dysbiosis, including bacterial overgrowth syndrome, as well as increasing intestinal permeability in the pathogenesis of the main pancreatic diseases: acute and chronic pancreatitis (AP and CP), autoimmune pancreatitis, pancreatic cancer.

Thus, according to the results of meta-analysis, populations of Enterobacteriaceae and Enterococcus were larger in all patients with AP as compared with healthy. There was no difference between the groups with severe and mild AP. Number of Bifidobacterium was lower in all patients with AP as compared with healthy. In severe AP, level of endotoxin and cytokines in blood was higher than in mild AP and in healthy.

Participation of Helicobacter pylori in pathogenesis of autoimmune pancreatitis via molecular mimicry is assumed. In addition, Helicobacter pylori may have significance in development of pancreatic adenocarcinoma.

In CP, rate of syndrome of bacterial overgrowth has been studied in numerous studies, since dysbiosis halts the effect of enzyme preparations, causes worsening of clinical manifestations. According to the results of meta-analysis, patients with CP are characterized by quantitative and qualitative changes in the composition of intestinal microbiome: decrease of Bifidobacterium and Lactobacillus, and increase of Enterobacteriaceae. The authors also preseented their own data.

Recent data suggest a connection between the oral microbiota, tongue plaque and pancreatic adenocarcinoma. Pancreatic cancer is characterized by decrease of Neisseria elongate, Streptococcus mitis, and increase of Porphyromonas gingivalis and Granulicatella adiacens. Recent reports have found that oral microbiota may be important in increasing the risk of pancreatic cancer. The conclusion is drawn on the prospects of studying the intestinal microbiota in pancreatic diseases and the need for its participation in the pathogenesis of this disease.
PDF (Русский)
DOCX (Українська)


Агафонова Н. А. Патология билиарного тракта как причина внешнесекреторной недостаточности поджелудочной железы и развития билиарного панкреатита. Consilium medicum. Гастроэнтерология. 2012. № 2. С. 26–30.
Ардатская М. Д., Минушкин О. Н. Синдром избыточного бактериального роста: определение, современные подходы к диагностике и лечебной коррекции. Consilium medicum. Гастроэнтерология. 2012. № 2. С. 45–49.
Губергриц Н. Б., Лукашевич Г. М. Кто виноват в том, что ферментные препараты не всегда достаточно эффективны: врач, пациент или поджелудочная железа? Вестник клуба панкреатологов. 2013. № 3. С. 13–19.
Дегтярева И. И. Клиническая гастроэнтерология. М.: Мед. информ. агентство, 2004. 616 с.
Коцаба Ю. Я., Бабінець Л. С., Малярчук А. Р. Клініко-патогенетичні особливості ентеропанкреатичного синдрому у хворих на хронічний панкреатит та його корекція на амбулаторному етапі. Вестник клуба панкреатологов. 2016. № 4. С. 33–35.
Линевский Ю. В., Линевская К. Ю., Воронин К. А. Синдром мальассимиляции и его лечение у больных хроническим панкреатитом. Вестник клуба панкреатологов. 2009. № 1. С. 60–63.
Парфенов А. И. Полиферментная заместительная терапия в лечении заболеваний кишечника. Справочник поликлинического врача. 2008. № 4. С. 43–46.
Плотникова Е. Ю. Основная проблема длительного приема ингибиторов протонной помпы. Вестник клуба панкреатологов. 2015. № 4. С. 76–80.
Сапроненков П. И. Иммунология желудочно-кишечного тракта. Л.: Наука, 1987. 158 с.
Ткач С. М., Пучков К. С., Сизенеко А. К. Кишечная микробиота в норме и при патологии: современные подходы к диагностике и коррекции кишечного дисбиоза. Киев: [Б. и.], 2014. 149 с.
Яковенко Э. П. Ферментные препараты в клинической практике. Клин. фармакол. и тер. 1998. № 1. С. 17–20.
Ярошенко Л. А. Патогенез и лечение синдрома избыточного бактериального роста в тонкой кишке у больных с сочетанием хронического панкреатита и хронического бронхита. Вестник клуба панкреатологов. 2014. № 2. С. 39–42.
Akshintala V. S., Talukdar R., Singh V. K., Goggins M. The gut microbiome in pancreatic disease. Clin. Gastroenterol. Hepatol. 2019. Vol. 17, Nо 2. P. 290–295.
Akyol S., Mas M. R., Comert B., Ateskan U., Yasar M., Aydogan H. et al. The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis. Pancreas. 2003. Vol. 26. P. 363–367.
Al-Omran M., Albalawi Z. H., Tashkandi M. F., Al-Ansary L. A. Enteral versus parenteral nutrition for acute pancreatitis. Cochrane Database Syst. Rev. 2010. CD002837.
Ammori B. J. Role of the gut in the course of severe acute pancreatitis. Pancreas. 2003. Vol. 26. P. 122–129.
Armougom F., Henry M., Vialettes B., Raccah D., Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One. 2009. Vol. 4. e7125.
Bajaj J. S., Heuman D. M., Sanyal A. J. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013. Vol. 8. e60042.
Banks P. A., Bollen T. L., Dervenis C., Gooszen H. G., Johnson C. D., Sarr M. G. et al. Classification of acute pancreatitis — 2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013. Vol. 62. P. 102–111.
Beger H. G., Rau B., Isenmann R. Natural history of necrotizing pancreatitis. Pancreatology. 2003. Vol. 3. P. 93–101.
Besselink M. G., van Santvoort H. C., Boermeester M. A., Nieuwenhuijs V. B., van Goor H., Dejong C. H. et al. Timing and impact of infections in acute pancreatitis. Br. J. Surg. 2009. Vol. 96. P. 267–273.
Besselink M. G., van Santvoort H. C., Buskens E., Boermeester M. A., van Goor H., Timmerman H. M. et al. Probiotic prophylaxis in patients with predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Ned. Tijdschr. Geneeskd. 2008. Vol. 152. P. 685–696.
Bongaerts G. P., Severijnen R. S. A reassessment of the PROPATRIA study and its implications for probiotic therapy. Nat. Biotechnol. 2016. Vol. 34. P. 55–63.
Capurso G., Zerboni G., Signoretti M., Valente R., Stigliano S., Piciucchi M. et al. Role of the gut barrier in acute pancreatitis. J. Clin. Gastroenterol. 2012. Vol. 46, Suppl. P. S46–51.
Capurso G., Signoretti M., Archibugi L. et al. Systematic review and meta-analysis: small intestinal bacterial overgrowth in chronic pancreatitis. UEG Journal. 2016. Vol. 4, Nо 5. P. 697–705.
Casellas F., Guarner L., Vaquero E. et al. Hydrogen breath test with glucose in exocrine pancreatic insufficiency. Pancreas. 1998. Vol. 16. P. 481–486.
Chang J. S., Tsai C. R., Chen L. T., Shan Y. S. Investigating the association between periodontal disease and risk of pancreatic cancer. Pancreas. 2016. Vol. 45. P. 134–141.
Chen X. Z., Schottker B., Castro F. A., Chen H., Zhang Y., Holleczek B. et al. Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: a ten-year follow-up of the ESTHER cohort study. Oncotarget. 2016. Vol. 7. P. 17182–17193.
Cheng J., Shah Y. M., Gonzalez F. J. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol. Sci. 2012. Vol. 33. P. 323–330.
Choung R. S., Ruff K. C., Malhotra A. et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment. Pharmacol. Ther. 2011. Vol. 33, Nо 9. P. 1059–1067.
Crookshank J. A. Where genes meet environ-ment-integrating the role of gut luminal contents, immunity and pancreas in type 1 diabetes. Transl. Res. 2017. Vol. 179. P. 183-98.
Di Stefano M., Malservisi S., Veneto G. et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 2000. Vol. 14. P. 551–556.
Dominguez-Munoz J. E. Pancreatic exocrine insufficiency: diagnosis and treatment. J. Gastroenterol. Hepatol. 2011. Vol. 26, Suppl. 2. P. 12–16.
Fan X., Alekseyenko A. V., Wu J., Peters B. A., Jacobs E. J. et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018. Vol. 67, Nо 1. P. 120–127.
Farrell J.J., Zhang L., Zhou H., Chia D., Elashoff D., Akin D. et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012. Vol. 61. P. 582–588.
Fishman J. E., Levy G., Alii V., Zheng X., Mole D. J., Deitch E. A. The intestinal mucus layer is a critical component of the gut barrier that is damaged during acute pancreatitis. Shock. 2014. Vol. 42. P. 264–270.
Fitzpatrick S. G., Katz J. The association between periodontal disease and cancer: a review of the literature. J. Dent. 2010. Vol. 38. P. 83–95.
Frost F., Kacprowski T., Rühlemann M., Bülow R., Kühn J.-P., Franke A. et al. Impaired exocrine pancreatic function associates with changes in intestinal microbiota composition and diversity. Gastroenterology. 2019. Vol. 156, No 4. P. 1010–1015.
Geller L. T., Barzily-Rokni M., Danino T., Jonas O. H., Shental N., Nejman D. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017. Vol. 357, No 6356. P. 1156–1160.
Gou S., Yang Z., Liu T., Wu H., Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit. Care. 2014. Vol. 18. P. R57.
Gracey M. Intestinal absorption in the “contaminated small bowel syndrome”. Gut. 1971. Vol. 12. P. 403–410.
Guarneri F., Guarneri C., Benvenga S. Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry? J. Cell Mol. Med. 2005. Vol. 9. P. 741–744.
Gubergrits N. B., Linevskiy Y. V., Lukashevich G. M. et al. Morphological and functional alterations of small intestine in chronic pancreatitis. JOP. 2012. Vol. 13, No 5. P. 519–528.
Haruta I., Shimizu K., Yanagisawa N., Shiratori K., Yagi J. Commensal flora, is it an unwelcomed companion as a triggering factor of autoimmune pancreatitis? Front Physiol. 2012. Vol. 3. P. 77.
Haruta I., Yanagisawa N., Kawamura S., Furukawa T., Shimizu K., Kato H. et al. A mouse model of autoimmune pancreatitis with salivary gland in volvement triggered by innate immunity via persistent exposure to avirulent bacteria. Lab. Invest. 2010. Vol. 90. P. 1757–1769.
Hauge T., Persson J., Danielsson D. Mucosal bacterial growth in the upper gastrointestinal tract in alcoholics (heavy drinkers). Digestion. 1997. Vol. 58. P. 591–595.
Huang J., Roosaar A., Axell T., Ye W. A prospective cohort study on poor oral hygiene and pancreatic cancer risk. Int. J. Cancer. 2016. Vol. 138. P. 340–347.
Kloppel G., Luttges J., Lohr M., Zamboni G., Longnecker D. Autoimmune pancreatitis: pathological, clinical, and immunological features. Pancreas. 2003. Vol. 27. P. 14–19.
Larsen N., Vogensen F. K., van den Berg F. W., Nielsen D. S., Andreasen A. S., Pedersen B. K. et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010. Vol. 5. P. e9085.
Lauritano E.C., Gabrielli M., Lupascu A. et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 2005. Vol. 22. P. 31–35.
Liu H., Li W., Wang X., Li J., Yu W. Early gut mucosal dysfunction in patients with acute pancreatitis. Pancreas. 2008. Vol. 36. P. 192–196.
Loguericio C. Gut microbiota and gastrointestinal tract, liver and pancreas: from phisiology to pathology. Torino: Edizioni Minerva Medica, 2018. 123 p.
Lohr J.-M., Heinemann V., Friess H. Pancreatic cancer. Bremen: Germany, Uni-Med, 2005. 160 p.
Lohr J. M., Faissner R., Koczan D., Bewerunge P., Bassi C., Brors B. et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am. J. Gastroenterol. 2010. Vol. 105. P. 2060–2071.
Lombardo L., Foti M., Ruggia O., Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol. 2010. Vol. 8, No 6. P. 504–508.
Lu H., Ren Z., Li A., Li J., Xu S., Zhang H. et al. Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. J. Oral Microbiol. 2019. Vol. 11, No 1. P. 1563409.
Madsen J. L., Graff J., Philipsen E. K. et al. Bile acid malabsorption or disturbed intestinal permeability in patients treated with enzyme substitution for exocrine pancreatic insufficiency is not caused by bacterial overgrowth. Pancreas. 2003. Vol. 26. P. 130–133.
Maisonneuve P., Amar S., Lowenfels A. B. Periodontal disease, edentulism and pancreatic cancer: a meta-analysis. Ann. Oncol. 2017. Vol. 28, No 5. P. 985–995.
Maisonneuve P., Lowenfels A. B. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int. J. Epidemiol. 2015. Vol. 44. P. 186–198.
Memba R., Duggan S. N., Ni Chonchubhair H. M., Griffin O. M., Bashir Y., O'Connor D. B. et al. The potential role of gut microbiota in pancreatic disease: a systematic review. Pancreatology. 2017. Vol. 17, No 6. P. 867–874.
Meyrat P., Safroneeva E., Schoepfe A. M. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment. Pharmacol. Ther. 2012. Vol. 36, No 11–12. P. 1084–1093.
Michaud D. S., Joshipura K., Giovannucci E., Fuchs C. S. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J. Natl. Cancer. Inst. 2007. Vol. 99. P. 171–175.
Morris G., Berk M., Carvalho A. F., Caso J. R., Sanz Y., Maes M. The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimmune processes with an emphasis on inflammatory bowel disease type 1 diabetes and chronic fatigue syndrome. Curr. Pharm. Des. 2016. Vol. 22. P. 6058–6075.
Muftuoglu M. A., Isikgor S., Tosun S., Saglam A. Effects of probiotics on the severity of experimental acute pancreatitis. Eur. J. Clin. Nutr. 2006. Vol. 60. P. 464–468.
Ní Chonchubhair H. M., Bashir Y., Dobson M., Ryan B. M., Duggan S. N., Conlon K. C. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology. 2018. Vol. 18, No 4. P. 379–385.
Ohshio G., Tanaka T., Suwa H., Imamura M. Immunoglobulin A secretion into pancreatic juice as a novel marker of local immune defense and exocrine pancreatic function. Dig. Dis. Sci. 2001. Vol. 46, No 10. P. 2140–2146.
Olah A., Issekutz A., Belagyi T., Hajdu N., Romics L. Jr. Randomized clinical trial of techniques for closure of the pancreatic remnant following distal pancreatectomy. Br. J. Surg. 2009. Vol. 96. P. 602–607.
Pancreatitis: medical and surgical management / Eds.: D. B. Adams et al. Chichester: Wiley Blackwell. 2017. 326 p.
Pancreatology: a clinical casebook / Eds.: T. B. Gardner, K. D. Smith. Cham (Switzerland): Springer International Publishing AG. 2017. 193 p.
Penalva J.C., Martinez J., Laveda R., Esteban A., Munoz C., Saez J. et al. A study of intestinal permeability in relation to the inflammatory response and plasma endocab IgM levels in patients with acute pancreatitis. J. Clin. Gastroenterol. 2004. Vol. 38. P. 512–517.
Pezzilli R., Zerbi A., Di Carlo V., Bassi C., Delle Fave G. F., Working Group of the Italian Association for the Study of the Pancreas on Acute Pancreatitis. Practical guidelines for acute pancreatitis. Pancreatology. 2010. Vol. 10. P. 523–535.
Pieramico O., Dominguez-Munoz J. E., Nelson D. K. et al. Interdigestive cycling in chronic pancreatitis: altered coordination among pancreatic secretion, motility, and hormones. Gastroenterology. 1995. Vol. 109. P. 224–230.
Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhea. Aliment. Pharmacol. Ther. 2016. Vol. 43, Suppl. 1. P. 37–49.
Ponziani F. R., Scaldaferri F., Petito V. et al. The role of antibiotics in gut microbiota modulation. Dig. Dis. 2016. Vol. 34, No 3. P. 269–278.
Qin H. L., Zheng J. J., Tong D. N., Chen W. X., Fan X. B., Hang X. M. et al. Effect of Lactobacillus plantarum enteral feeding on the gut permeability and septic complications in the patients with acute pancreatitis. Eur. J. Clin. Nutr. 2008. Vol. 62. P. 923–930.
Risch H. A. Pancreatic cancer: Helicobacter pylori colonization, N-nitrosamine exposures, and ABO blood group. Mol. Carcinog. 2012. Vol. 51. P. 109–118.
Scarpellini E., Gabrielli M., Lauritano C. E. et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 2007. Vol. 25. P. 781–786.
Scarpellini E., Giorgio V., Gabrielli M. et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome: a preliminary study. Eur. Rev. Med. Pharmacol. Sci. 2013. Vol. 17. P. 1314–1320.
Scarpignato C., Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005. Vol. 51, Suppl. 1. Р. 36–66.
Schwabe R. F., Jobin C. The microbiome and cancer. Nat. Rev. Cancer. 2013. Vol. 13. P. 800–812.
Senocak R., Yigit T., Kilbas Z., Coskun A. K., Harlak A., Mentes M. O. et al. The effects of total colectomy on bacterial translocation in a model of acute pancreatitis. Indian J. Surg. 2015. Vol. 77. P. 412–418.
Shah S. C., Day L. W., Somsouk M. et al. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 2013. Vol. 38. P. 925–934.
Shen J., Obin M. S., Zhao L. The gut microbiota, obesity and insulin resistance. Mol. Aspects Med. 2013. Vol. 34. P. 39–58.
Signoretti M., Stigliano S., Valente R. et al. Small intestinal bacterial overgrowth in patients with chronic pancreatitis. J. Clin. Gastroenterol. 2014. Vol. 48, Suppl. 1. P. S52–S55.
Tan C., Ling Z., Huang Y., Cao Y., Liu Q., Cai T. et al. Dysbiosis of intestinal microbiota associated with inflammation involved in the progression of acute pancreatitis. Pancreas. 2015. Vol. 44, No 6. P. 868–875.
Tenner S., Baillie J., DeWitt J., Vege S. S. American College of Gastroenterology guideline: management of acute pancreatitis. Am. J. Gastroenterol. 2013. Vol. 108. P. 1400–1415.
The pancreas: an integrated textbook of basic science, medicine and surgery / Ed. H. G. Beger, A. L. Warshaw, R. H. Hruban et al. Oxford: Willey Blackwell. 2018. 1173 p.
Therrien A., Bouchard S., Sidani S., Bouin M. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: a case-control study. Canadian J. Gastroenterol. Hepatol. 2016. Vol. 2016. P. 1-7.
Trespi E., Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr. Med. Res. Opin. 1999. Vol. 15, No 1. P. 47–52.
Tsuji Y., Watanabe T., Kudo M., Arai H., Strober W., Chiba T. Sensing of commensal organisms by the intracellular sensor NODI mediates experimental pancreatitis. Immunity. 2012. Vol. 37. P. 326–338.
Van Felius I. D., Akkermans L. M., Bosscha K., Verheem A., Harmsen W., Visser M. R. et al. Interdigestive small bowel motility and duodenal bacterial overgrowth in experimental acute pancreatitis. Neurogastroenterol. Motil. 2003. Vol. 15. P. 267–276.
Vege S. S., Chari S. T. Organ failure as an indicator of severity of acute pancreatitis: time to revisit the Atlanta classification. Gastroenterology. 2005. Vol. 128. P. 1133–1135.
Vonlaufen A., Spahr L., Apte M. V., Frossard J. L. Alcoholic pancreatitis: a tale of spirits and bacteria. World J. Gastrointest. Pathophysiol. 2014. Vol. 5. P. 82–90.
Wall I., Badalov N., Baradarian R., Iswara K., Li J. J, Tenner S. Decreased mortality in acute pancreatitis related to early aggressive hydration. Pancreas. 2011. Vol. 40. P. 547–550.
Wang Y., Zhang F. C., Wang Y. J. Helicobacter pylori and pancreatic cancer risk: a meta-analysis based on 2,049 cases and 2,861 controls. Asian Рас. J. Cancer Prev. 2014. Vol. 15. P. 4449–4454.
Wu L.M., Sankaran S.J., Plank L. D., Windsor J. A., Petrov M. S. Meta-analysis of gut barrier dysfunction in patients with acute pancreatitis. Br. J. Surg. 2014. Vol. 101. P. 1644–1656.
Xiao M., Wang Y., Gao Y. Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis. PLoS One. 2013. Vol. 8. P. e75559.
Xu D., Gao J., Gillilland M. et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014. Vol. 146, No 2. P. 484–496.
Zambirinis C. P., Pushalkar S., Saxena D., Miller G. Pancreatic cancer, inflammation, and microbiome. Cancer. J. 2014. Vol. 20. P. 195–202.